High incidence of antifungal drug resistance in Candida tropicalis

International Journal of Antimicrobial Agents

Volumn 7, Issue 4, 1996, Pages 241-245

  Law, D ^a   Moore, C B ^a   Joseph, L A ^a   Keaney, M G L ^a   Denning, D W ^a,b  

^a HOPE HOSPITAL   (United Kingdom)

^b NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; PYRROLE DERIVATIVE;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA TROPICALIS; CONTROLLED STUDY; CROSS RESISTANCE; DRUG RESISTANCE; INTENSIVE CARE UNIT; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; UNITED KINGDOM; YEAST;

EID: 0030266339     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(96)00328-7     Document Type: Article

References (21)

1. [1] Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC. Candidemia in a tertiary care hospital: epidemiology, risk factors and predictors of mortality. Clin Infect Dis, 1992;15:414-421.
2. [2] Price MF, LaRocco MT, Gentry LO. Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrobial Agents Chemother, 1994;38:1422-1424.
3. [3] Barnes AJ, Oppenheim BA. Candidaemia in hospitalised patients: the recent emergence of Candida tropicalis as a significant pathogen. Abstract. Trends in Invasive Fungal Infections. Brussels, 1995.
4. [4] Wellmer A, Schulz K, Wiersbitsky M, Zinke H, Kawohl F, Bernhardt H. Changes in the frequency of different fungal isolates on a medical ICU from 1992 to 1994. Abstract. Trends in Invasive Fungal Infections. Brussels, 1995.
5. [5] Working Party of the British Society for Antimicrobial Chemotherapy. Chemoprophylaxis for candidosis and aspergillosis in neutropenia and transplantation: a review and recommendations. J Antimicrobial Chemother, 1993;32:5-21.
6. [6] Law D, Moore CB, Wardle HM, Joseph LA, Keaney MGL, Denning DW. High prevalence of antifungal resistance in Candida spp. from patients with AIDS. J Antimicrobial Chemother, 1994;34:659-668.
7. [7] Odds FC. Resistance of yeasts to azole-derivative antifungals. J Antimicrobial Chemother, 1993;31:463-471.
8. [8] Denning DW, Can we prevent azole resistance in fungi? Lancet, 1995;346:454-455.
9. [9] Johnson EM, Warnock DW, Luker J, Porter SR, Scully C. Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis. J Antimicrobial Chemother, 1995;35:103-114.
10. [10] Berenguer J, Fernandez-Baca V, Sanchez R, Bouza E. In vitro activity of amphotericin B, flucytosine and fluconazole against yeasts causing bloodstream infections. Eur J Clin Microbiol Infect Dis, 1995;14:363-365.
11. [11] Report of a Working Group of the British Society for Mycopathology. Laboratory methods for flucytosine (5-fluorocytosine). J Antimicrobial Chemother, 1984;14:1-8.
12. [12] Rex JH, Cooper Jr CR, Merz WG. Galgiani JN, Anaissie FJ. Detection of amphotericin B-resistant Candida species in a broth-based system. Antimicrobial Agents Chemother, 1995;31:463-471.
13. [13] Baily GG, Perry FM, Denning DW, Mandal BK. Management of candidiasis after failure of fluconazole in an HIV cohort. AIDS, 1994;8:787-792.
14. [14] Pfaller MA, Bale M, Buschelman B, Lancaster M, Espinel-Ingroff A, Rex JH, Rinaldi MG. Selection of candidate quality control isolates and tentative quality control isolates and tentative quality control ranges for in vitro susceptibility testing of yeast isolates by National Committee for Clinical Laboratory Standards proposed standard methods. J Clin Microbiol, 1994;32:1650-1653.
15. [15] Johnson EM, Davey KG, Szekely A, Warnock DW. Itraconazole suceptibilities of fluconazole susceptible and resistant isolates of five Candida species. J Antimicrobial Chemother, 1995;36:787-794.
16. [16] Wardle H M, Law D, Moore C B, Mason C M, Denning D W. The in vitro activity of D0870 compared with other azoles against fluconazole resistant Candida spp. Antimicrobial Agents Chemother, 1995;39:868-871.
17. [17] British Society for Antimicrobial Chemotherapy Working Party on Fungal Infection. Management of deep Candida infection in the surgical and intensive care unit patient. Intensive Care Med, 1994;20:522-528.
18. [18] Guttierrez F. An analysis of the trends in the use of antifungal drugs and fungal isolates in a UK university hospital. J Hosp Infect, 1995;31:149-151.
19. [19] Pfaller M, Cabezudo I, Koontz F, Bale M, Gingrich R. Predictive value of surveillance cultures for systemic infection due to Candida species. Eur J Clin Microbiol, 1987;6:628-633.
20. [20] Sandford GR, Merz WG, Wingard JR, Charache P, Saral R. 1980. The value of fungal surveillance cultures as predictors of systemic fungal infections. J Infect Dis, 1980;142:503-509.
21. [21] Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, Washburn RG, Scheld WM, Karchmer AW, Dine AP et al. 1994. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the NIAID Mycoses Study Group. N Engl J Med, 1994;331:1325-1330.